Open AccessOcclusive Retinal Vasculitis Following Intravitreal Brolucizumab
Author(s) -
André J. Witkin,
Paul Hahn,
Timothy G. Murray,
J. Fernando Arévalo,
Kevin J. Blinder,
Netan Choudhry,
Geoff G Emerson,
Roger A. Goldberg,
Stephen J. Kim,
Joel Pearlman,
Eric Schneider,
Homayoun Tabandeh,
Robert W. Wong
Publication year - 2020
Publication title -
journal of vitreoretinal diseases
Language(s) - English
Resource type - Journals
eISSN - 2474-1272
pISSN - 2474-1264
DOI - 10.1177/2474126420930863
Subject(s) - retinal vasculitis , medicine , retinal , vasculitis , ophthalmology , asymptomatic , macular degeneration , visual acuity , adverse effect , retina , surgery , pathology , disease , physics , optics
To analyze a case series of retinal vasculitis reported to the American Society of Retina Specialists (ASRS) following Food and Drug Administration approval of brolucizumab for treatment of neovascular age-related macular degeneration.